Related Experiment Videos

[Clinical study on effect of Shenmai Injection in treating congestive heart failure]

Ming-zhi Long1, Di-bin Wang, Ji-ming Yang

  • 1Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011. Longmzh@hotmail.com

Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi = Chinese Journal of Integrated Traditional and Western Medicine
|December 12, 2003
PubMed

Insights

Shenmai Injection (SI) effectively treats congestive heart failure (CHF) by improving hemodynamics and heart function. Serum cardiac troponin T (cTnT) levels can predict patient prognosis, with SI showing a safe therapeutic profile.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Congestive heart failure (CHF) is a complex syndrome characterized by impaired cardiac function.
  • Biomarkers like cardiac troponin T (cTnT) are crucial for assessing myocardial injury in CHF.

Purpose of the Study:

  • To evaluate the therapeutic efficacy of Shenmai Injection (SI) in patients with congestive heart failure (CHF).
  • To assess the role of serum cTnT as a prognostic indicator in CHF patients treated with SI.

Main Methods:

  • A randomized controlled trial involving 62 chronic CHF patients comparing routine treatment with routine treatment plus SI.
  • Monitoring of cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP), serum cTnT, creatine kinase (CK), and creatine kinase isoenzyme (CK-MB).

Main Results:

  • SI treatment for 2 weeks stabilized hemodynamics and significantly improved heart function in CHF patients.
  • Serum cTnT levels correlated with heart function deterioration, suggesting its prognostic value.
  • No serious adverse reactions were reported during the SI treatment course.

Conclusions:

  • Shenmai Injection (SI) demonstrates effectiveness and safety as an adjunct therapy for congestive heart failure (CHF).
  • Serum cTnT is a reliable biochemical marker for predicting the prognosis of CHF patients.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...